Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?

Area of Science:

• Immunology
• Pharmacology
• Biotechnology

Background:

• Immune-mediated inflammatory diseases share pathogenic pathways, enabling potential extrapolation of therapeutic data.
• Biosimilars are highly similar to reference biotherapeutic products in quality, safety, and efficacy.

Purpose of the Study:

• To review the scientific basis for extrapolation of biosimilar data across indications.
• To examine the current biosimilar approval process and early studies in rheumatoid arthritis.
• To assess the suitability of extrapolation to inflammatory bowel diseases.

Main Methods:

• Review of scientific literature on biosimilar extrapolation and analytical characterization.
• Analysis of clinical data from biosimilar studies, particularly in rheumatoid arthritis.
• Evaluation of immunogenicity and post-translational modification data.

Main Results:

• Biosimilars share the same amino acid sequence as their reference products, but structural nuances may persist.
• Extrapolation of biosimilar efficacy from rheumatoid arthritis to other indications, like inflammatory bowel diseases, requires further investigation.
• CT-P13 (infliximab biosimilar) shows promise but needs more data for robust extrapolation to inflammatory bowel diseases.

Conclusions:

• Extrapolation of biosimilar data is feasible but requires careful consideration of disease pathways and immunogenicity.
• Robust pharmacovigilance is essential to monitor for immunogenicity and adverse effects of biosimilars.
• Additional studies are needed to confirm biosimilar extrapolation from rheumatoid arthritis and ankylosing spondylitis to inflammatory bowel diseases.